Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy
AL Zarling, JM Polefrone, AM Evans… - Proceedings of the …, 2006 - National Acad Sciences
AL Zarling, JM Polefrone, AM Evans, LM Mikesh, J Shabanowitz, ST Lewis, VH Engelhard…
Proceedings of the National Academy of Sciences, 2006•National Acad SciencesAlterations in phosphorylation of cellular proteins are a hallmark of malignant transformation.
Degradation of these phosphoproteins could generate cancer-specific class I MHC-
associated phosphopeptides recognizable by CD8+ T lymphocytes. In a comparative
analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma,
and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and
common to both cancers. Differential presentation of these peptides can result from …
Degradation of these phosphoproteins could generate cancer-specific class I MHC-
associated phosphopeptides recognizable by CD8+ T lymphocytes. In a comparative
analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma,
and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and
common to both cancers. Differential presentation of these peptides can result from …
Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphoproteins could generate cancer-specific class I MHC-associated phosphopeptides recognizable by CD8+ T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopeptide-specific CD8+ T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.
National Acad Sciences